Lemaitre Vascular (LMAT) Cost of Revenue (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Cost of Revenue data on file, last reported at $14.5 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $14.5 million, up 2.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.3 million (up 41.15% YoY), and the FY2025 annual result was $54.5 million, up 16.53% from the prior year.
• Cost of Revenue rose to $14.5 million in Q1 2026 per LMAT's latest filing, from $13.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $35.6 million in Q4 2023 and troughed at -$5.1 million in Q4 2024.
• A 5-year average of $14.3 million and a median of $14.3 million in 2022 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue tumbled 114.3% in 2024, then soared 363.52% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $14.9 million in 2022, then soared by 139.26% to $35.6 million in 2023, then plunged by 114.3% to -$5.1 million in 2024, then soared by 363.52% to $13.4 million in 2025, then advanced by 8.05% to $14.5 million in 2026.
• Business Quant data shows LMAT's Cost of Revenue at $14.5 million in Q1 2026, $13.4 million in Q4 2025, and $15.1 million in Q3 2025.